Ruitao Lin

BAP: Bayesian Biomarker-Assisted Platform Design for Dose Ranging in Multi-Agent Multi-Dose Trials

Assessing the long-term benefits of new treatments can be expensive and time-consuming, particularly in disease areas with unmet medical needs. While platform trials enable the evaluation of multiple interventions simultaneously, they currently cannot assess studies involving mul...